Latest by Sean R. Hosein
In late June 2017, Health Canada licensed the sale and use of a new formulation of the anti-HIV drug raltegravir (Isentress) as part of the treatment of HIV.
Researchers in San Diego, Calif., said that having both "mental health and substance diagnoses" was not a barrier to successful HCV treatment.
For homeless people who may be reluctant to engage with hospital-based services, researchers in Brighton, England established a liver monitoring and care service located in the community that focused on people 40 years and older.
Researchers conducted a study to assess the impact of direct-acting antivirals on issues such as mood and factors affected by mood, such as physical activity and fatigue.
Researchers found that people who were cured of hepatitis C virus underwent "significant improvement" in blood sugar levels and in many cases participants' doctors were able to reduce the dose of medicines used to help control blood sugar.
Researchers found that HIV-positive Indigenous people who were prescribed antiretroviral therapy continued to have elevated rates of death compared to non-Indigenous people.
Researchers at the British Columbia Centre for Excellence in HIV/AIDS along with other researchers in Vancouver have attempted to study the relative impact that ART, harm reduction or both can have on the spread of HIV.
A study has shown that a nurse-led intervention called AIMS (Adherence Improving self-Management Strategy) has had a measurable and significant effect on improving treatment success rates.
A recent clinical trial found that doravirine was roughly equivalent in potency to darunavir-based regimens.
At the recent Conference on Retroviruses and Opportunistic Infections, researchers presented data about 5 new anti-HIV compounds in development.